BioCentury
ARTICLE | Company News

Biota and Glaxo influenza deal

September 5, 2000 7:00 AM UTC

Biota Holdings (ASX:BTA) and Glaxo (GLX; LSE:GLXO) will develop and market worldwide a second-generation viral neuraminidase inhibitor to treat influenza infection. The companies will fund their own R&D costs to the point of selecting a lead compound for clinical development, after which GLX will fund the program through to the market. BTA is eligible for milestones and royalties. ...